Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Matthews

Showing results (281-290 of 293) with videos related to

Pageof 30
Sort By:
The Lancet. HIV|January 15, 2024
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studiesRachel Sacks-Davis, Daniela K van Santen, Anders Boyd, et al.
Journal of the American College of Cardiology|July 5, 2005
Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trialsStefan H Ostermayer, Mark Reisman, Paul H Kramer, et al.
The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.
The International Journal on Drug Policy|October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyEvan B Cunningham, Janaki Amin, Jordan J Feld, et al.
Frontiers in Immunology|December 22, 2022
High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cellsChansavath Phetsouphanh, Weng Hua Khoo, Katherine Jackson, et al.
The Lancet. Gastroenterology & Hepatology|January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trialJason Grebely, Olav Dalgard, Brian Conway, et al.
Plos Medicine|July 6, 2021
SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variantsFiona Tea, Alberto Ospina Stella, Anupriya Aggarwal, et al.
Med (New York, N.Y.)|August 13, 2022
Lessons from an international trial evaluating vaccination strategies for recovered inpatients with COVID-19 (VATICO)Eleftherios Mylonakis, Joseph Lutaakome, Mamta K Jain, et al.
Scientific Reports|March 22, 2025
SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial)Sofía Sábato, Susana Benet, Angela J Rogers, et al.
The Journal of Infectious Diseases|September 13, 2024
Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019Cavan Reilly, Eleftherios Mylonakis, Robin Dewar, et al.
Pageof 30

Showing results (281-290 of 293) with videos related to

Sort By:
Pageof 30
The Lancet. HIV|January 15, 2024
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studiesRachel Sacks-Davis, Daniela K van Santen, Anders Boyd, et al.
Journal of the American College of Cardiology|July 5, 2005
Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trialsStefan H Ostermayer, Mark Reisman, Paul H Kramer, et al.
The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.
The International Journal on Drug Policy|October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyEvan B Cunningham, Janaki Amin, Jordan J Feld, et al.
Frontiers in Immunology|December 22, 2022
High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cellsChansavath Phetsouphanh, Weng Hua Khoo, Katherine Jackson, et al.
The Lancet. Gastroenterology & Hepatology|January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trialJason Grebely, Olav Dalgard, Brian Conway, et al.
Plos Medicine|July 6, 2021
SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variantsFiona Tea, Alberto Ospina Stella, Anupriya Aggarwal, et al.
Med (New York, N.Y.)|August 13, 2022
Lessons from an international trial evaluating vaccination strategies for recovered inpatients with COVID-19 (VATICO)Eleftherios Mylonakis, Joseph Lutaakome, Mamta K Jain, et al.
Scientific Reports|March 22, 2025
SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial)Sofía Sábato, Susana Benet, Angela J Rogers, et al.
The Journal of Infectious Diseases|September 13, 2024
Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019Cavan Reilly, Eleftherios Mylonakis, Robin Dewar, et al.
Pageof 30